Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the effects of levomilnacipran extended-release (ER) on suicidal ideation and behavior in adults with major depressive disorder (MDD). Methods: Post hoc analyses were conducted in patients from 4 randomized, double-blind, placebo-controlled trials and a long-term, open-label extension study of levomilnacipran ER (40-120 mg/d) in adults with MDD. Analyses included incidence of suicide-related treatment-emergent adverse events (TEAEs); incidence of Columbia–Suicide Severity Rating Scale (C-SSRS) suicidal ideation (score=1–5) and behavior (score=6-10); percent of patients who shifted from no C-SSRS suicidal ideation/behavior at baseline to suicidal ideation during treatment (worsened from score=0 to score=1–5), or vice-versa (improved from score=1-5 to score=0). Results: Suicide-related TEAEs occurred in<1% of patients in the levomilnacipran ER studies. The incidence of C-SSRS suicidal ideation was 22.2%, 23.9%, and 21.7% for placebo, short-term levomilnacipran ER, and long-term levomilnacipran ER, respectively; C-SSRS suicidal behavior was<1% in all of these groups. In the short-term studies, the percentage of patients with C-SSRS shifts were as follows: worsening from score=0 to score=1–5 (placebo, 8.6%; levomilnacipran ER, 11.0%); improvement from score=1–5 to score=0 (placebo, 24.0%; levomilnacipran ER, 27.7%). Conclusion: In adult MDD patients, the incidence of suicidal ideation and behavior was similar between placebo and short-term levomilnacipran ER as indicated by TEAE reports and C-SSRS scores. Worsening in C-SSRS scores was also similar between placebo and levomilnacipran ER. There was no indication of increased suicidality during longer courses of continued therapy. Together, these findings suggest that this medication is not associated with increased risks of suicidal ideation or behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Contrary to earlier FDA findings, SSRIs may work without increasing risk of treatment-emergent suicidal ideation or behavior, even in youth.(67–69)”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [69]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“The C-SSRS was specifically developed to quantify the severity of suicidal ideation and behavior following C-CASA guidelines.(19,20) As recommended, the C-SSRS was used in addition to adverse event (AE) reporting to monitor suicidal ideation and behavior in 4 US clinical trials of levomilnacipran extendedrelease (ER),…”
Suicide Prevention Strategies: A Systematic Review
Mann, J. J., Apter, A., Bertolote, J., Beautrais, A., Currier, D., Haas, A., Hegerl, U., Lonnqvist, J., Malone, K., Marusic, A., et al. (2005) · JAMA · doi:10.1001/jama.294.16.2064 · Cited by 2,852 · cited 1×
“5% of the global burden of disease, with psychiatric disorders contributing to approximately 90% of suicides; mood disorders (primarily major depressive disorder [MDD]) account for approximately 60% of suicides.(1) A Canadian Community Health Study survey found that in respondents who had MDD, the 12-month prevalence…”
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054 · cited 1×
“8 – 10 Based on meta-analyses of clinical trials conducted in pediatric populations and younger adults (18 – 24 years of age), 11,12 a black-box warning for increased risk of suicidal ideation and behavior in these populations is now required by the US Food and Drug Administration (FDA) for all…”
Posner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025 · cited 1×
“The C-SSRS was specifically developed to quantify the severity of suicidal ideation and behavior following C-CASA guidelines.(19,20) As recommended, the C-SSRS was used in addition to adverse event (AE) reporting to monitor suicidal ideation and behavior in 4 US clinical trials of levomilnacipran extendedrelease (ER),…”
Borges, G., Nock, M. K., Haro Abad, J. M., Hwang, I., Sampson, N. A., Alonso, J., Andrade, L. H., Angermeyer, M. C., Beautrais, A., Bromet, E., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04967blu · Cited by 796
Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009) · BMJ · doi:10.1136/bmj.b2880 · Cited by 609
Oquendo, M. A., Galfalvy, H., Russo, S., Ellis, S. P., Grunebaum, M. F., Burke, A., & Mann, J. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1433 · Cited by 605
Fergusson, D., Doucette, S., Glass, K. C., Shapiro, S., Healy, D., Hebert, P., & Hutton, B. (2005) · BMJ · doi:10.1136/bmj.330.7488.396 · Cited by 510 · cited 1×
“Some meta-analyses have found an increased risk of suicidality with antidepressants, particularly with older serotonin reuptake inhibitors, 13 – 15 while other meta-analyses found no increased risk of suicide-related events in older adults.”
Khan, A., Khan, S., Kolts, R., & Brown, W. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.790 · Cited by 394 · cited 1×
“Some meta-analyses have found an increased risk of suicidality with antidepressants, particularly with older serotonin reuptake inhibitors, while other meta-analyses found no increased risk of suicide-related events in older adults.(12,16) Nonetheless, prescribing information for FDA-approved antidepressants generally…”
Self-citationReligion and Suicide Risk: A Systematic Review
Lawrence, R. E., Oquendo, M. A., & Stanley, B. (2016) · Archives of Suicide Research · doi:10.1080/13811118.2015.1004494 · Cited by 390 · cited 1×
“32 Given the small number of reported suicide-related events in the levomilnacipran ER studies, adjusting for such factors would probably not have been meaningful.”
Research works printed but not linked: 1
- 17. M. E. THASE ET AL. https://doi.org/10.1017/S1092852916000663 Published online by Cambridge University Press
Cited by
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060864 · Cited by 655
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021004 · Cited by 39
Mahableshwarkar, A. R., Affinito, J., Reines, E. H., Xu, J., Nomikos, G. G., & Jacobsen, P. L. (2019) · CNS Spectrums · doi:10.1017/s109285291900097x · Cited by 17
Boldrini, M., & Mann, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00039-3 · Cited by 9
Efficacy of levomilnacipran extended release in treating major depressive disorder
Ragguett, R., Yim, S. J., Ho, P. T., & McIntyre, R. S. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1410540 · Cited by 8
“A post hoc analysis on four short-term and one long-term levomilnacipran ER trials demonstrated that suicidal ideation and/or behavioral are not increased with levomilnacipran ER use, a limitation however introduced by the authors is that these results may vary with long-term usage [33].”
Background
Metadata
- Authors
- Thase, M. E., Gommoll, C., Chen, C., Kramer, K., Khan, A., & Durgam, S.
- Affiliations
- University of Pennsylvania (US)
- Allergan (United States) (US)
- Duke University (US)
- Corresponding author
- Thase, Michael E.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2017-05-19
- Volume
- 22
- Issue
- 6
- Pages
- 475-483
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W2614241956
- Cited by
- 6
- References
- 31
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 2 · 2019: 1 · 2017: 1
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- CNS Spectrums (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- levomilnacipran, major depressive disorder, suicidality, suicidal ideation, suicidal behavior, Columbia Suicide Severity Rating Scale, treatment-emergent adverse events, serotonin reuptake inhibitors, antidepressant safety
- MeSH terms
- Levomilnacipran, Antidepressive Agents, Delayed-Action Preparations, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Humans, Suicide, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. https://app.cochat.ai/papers/10.1017/s1092852916000663
- The paper
- Thase, M. E., Gommoll, C., Chen, C., Kramer, K., Khan, A., & Durgam, S. (2017). Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. CNS Spectrums. https://doi.org/10.1017/s1092852916000663
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.